ReviewProbiotics and antimicrobial proteins2024
Lactococcus lactis as an Interleukin Delivery System for Prophylaxis and Treatment of Inflammatory and Autoimmune Diseases.
Review in Probiotics and antimicrobial proteins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- Probiotics unveiled: bridging general health benefits to the era of precision medicine.World journal of microbiology & biotechnology · 2026Review
- Targeting the Human Gut Microbiota-Between Conventional Therapy and Precision Genetic Engineering.Nutrients · 2026Review
- Gut Microbiota and Chronic Kidney Disease: A Complex Interplay with Implications for Diagnosis and Treatment.Probiotics and antimicrobial proteins · 2026Review
- Genetically Modified Lactic Acid Bacteria in the EU Food Chain: Applications, Benefits, and Risk Assessment.International journal of molecular sciences · 2026Review
- Control of immunogenic responses of microorganism-synthesized biopolymers for 3D bioprinting tissue engineering and regenerative medicine.Bioactive materials · 2026Review
- Host interactions ofApplied and environmental microbiology · 2025Article
- A Genomic Investigation into the Probiotic Attributes Among Members of the Lactobacillaceae family.Current microbiology · 2025Article
- Effects ofAnimals : an open access journal from MDPI · 2025Article
- Genetically Engineered Probiotics: Design, Therapeutics, and Clinical Translation.Iranian biomedical journal · 2025Review
- Exploring the role of gut microbiota in inflammatory bowel disease patients comorbid with non-alcoholic fatty liver disease.Gut pathogens · 2025Article
- Role of tumor microenvironment in cancer promotion, development of drug resistance and cancer treatment.Journal of the Egyptian National Cancer Institute · 2025Review
- Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease.Clinical and molecular hepatology · 2025Review
- A Point Mutation in Cassette Relieves the Repression Regulation of CcpA Resulting in an Increase in the Degradation of 2,3-Butanediol inMicroorganisms · 2024Article
- The strain-dependent cytostatic activity of Lactococcus lactis on CRC cell lines is mediated through the release of arginine deiminase.Microbial cell factories · 2024Article
- Engineering Probiotics for Diabetes Management: Advances, Challenges, and Future Directions in Translational Microbiology.International journal of nanomedicine · 2024Review
- The potential use of bacteria and bacterial derivatives as drug delivery systems for viral infection.Virology journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Target delivery of therapeutic agents with anti-inflammatory properties using probiotics as delivery and recombinant protein expression vehicles is a promising approach for the prevention and treatment of many diseases, such as cancer and intestinal immune disorders. Lactococcus lactis, a Lactic Acid Bacteria (LAB) widely used in the dairy industry, is one of the most important microorganisms with GRAS status for human consumption, for which biotechnological tools have already been developed to express and deliver recombinant biomolecules with anti-inflammatory properties. Cytokines, for example, are immune system communication molecules present at virtually all levels of the immune response. They are essential in cellular and humoral processes, such as hampering inflammation or adjuvating in the adaptive immune response, making them good candidates for therapeutic approaches. This review discusses the advances in the development of new therapies and prophylactic approaches using LAB to deliver/express cytokines for the treatment of inflammatory and autoimmune diseases in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.